Jingtai Technology announces completion of acquisition of Liverpool LCC Chemical Technology Company in the UK

On June 12, 2025, Jingtai Technology (Jingtai Holdings, XTALPI),2228.HK）Announced completion of LiverpoolChiroChem in the UK（LCC）The acquisition of the technology company further enhances the strength of Jingtai's "AI+Robot" intelligent autonomous experimental platform in the field of chemical space exploration, and will better serve customers in the fields of new drug research and development, new material discovery, and high-value chemicals at home and abroad.

LCC Technology Company was founded in 2014 at the University of Liverpool in the UK, and has long been committed to the design and synthesis technology research and development of novel molecules, especially novel chiral molecules. PACE developed by the company（The Parallel Automated Chiral Engine technology platform combines AI software and automation technology to virtually screen target molecules in a chiral chemical library of billions of molecules, and efficiently complete synthesis and physical testing with the help of automated equipment. The platform has served multiple well-known multinational pharmaceutical companies.

At the same time, the company's long-term accumulation of chiral chemical molecule entity libraries and databases has achieved technological leadership in molecular weight and diversity, which can provide high-quality data support for artificial intelligence models in the exploration of chiral molecular chemistry space.

In addition, LCC Technology Company has accumulated complete technical solutions in the field of high-throughput and trace molecule library construction, which complement the advantages of the large-scale molecule library construction technology of Jingtai Technology's intelligent independent experimental platform.

Dr. Paul Colbon, Founder and CEO of LCC Technology CompanyIn 2020, the research results of the University of Liverpool's research group on AI chemical robots appeared on the cover of Nature magazine. Anthony Huxley and I (the head of the company's chemistry department) are pleased to see that this concept has been widely applied in the industry today. We look forward to working with Jingtai Technology to utilize cutting-edge technologies such as AI and robotics combined with high-quality data to explore a broader chemical space and help customers find high-value molecules faster. ”

Dr. Paul Colbon, Founder and CEO of LCC (first from left)

Taking a photo with the R&D team in the UK office

At the same time, our Science Advisory Board (SAB), including Dr. Chris Swain and Dr. Stevan Djuric, is also looking forward to this collaboration - LCC's proud achievements in chiral chemistry, if we can use innovative technologies such as AI and robotics to serve pharmaceutical companies faster and better, it will accelerate the healing of more people. ”

Through strategic cooperation, incubation, joint research and development, mergers and acquisitions, Jingtai Technology's technological strength in the field of chemical space exploration continues to strengthen, and its ability to serve overseas customers has been further enhanced.